FDA Takes Actions to Secure Safety of Compounded Drugs

25 July 2018

BioPrarm International

The agency announced two research collaborations on bulk lists, updates to categories of bulk drug substances, and issued a warning about a bulk drug substance used in compounding.

On July 23, 2018, FDA announced efforts to protect public health by taking actions regarding drug compounding. The efforts are part of the implementation of the Drug Quality and Security Act and the agency’s 2018 Compounding Policy Priorities Plan. These new actions focus on bulk drug substances used in compounding.

“Addressing bulk drug substances used in compounding is an important priority for the agency,” said Anna Abram, Deputy Commissioner for FDA’s Policy, Planning, Legislation and Analysis, in a press statement. “The FDA seeks to implement the statutory requirements for bulk drug substances that can be used in compounding in a way that strikes a balance between preserving access to compounded drugs for patients who have a medical need for them while reducing the safety risks and protecting the FDA drug approval process. Input from stakeholders, including healthcare professionals, is critical to achieving this balance.”

As part of these efforts, the agency issued an alert on July 23 about the risk of cesium chloride, which is sometimes used by cancer patients, and announced it was moving the substance to category 2 under the agency’s interim policy on compounding with bulk drug substances under section 503A of the Food, Drug, and Cosmetic Act (FD&C). FDA stated that cesium chloride has not been proven safe or effective and possible serious adverse events associated with the use of the ingredient include abnormal heart rhythms, low potassium, seizures, fainting, cardiac arrest, and death.

According to FDA, category 2 bulk drug substances are substances nominated with sufficient supporting information to be evaluated by FDA for their eligibility to be included in the 503A bulks list but raise significant safety risks in compounding.  The agency intends to take regulatory action against compounders that use category 2 substances.

To develop a list of bulk drug substances compounded under section 503B of the FD&C, FDA will be working with the University of Maryland and Johns Hopkins University to gather and analyze information. The University of Maryland will work with medical specialty groups about the use of drug products in clinical practice. Johns Hopkins will study safety and effectiveness information on bulk drug substances used in compounding drugs for patients with autism.

The agency is also working to update the categories of substances that are subject to FDA’s interim policies on compounding bulk drug substances. Newly nominated or re-nominated substances with adequate support that do not present significant safety risk will be placed in category 1. Substances without adequate support will be placed in category 3 and will not be eligible for the interim policies.

“The FDA designed its interim policies to avoid unnecessary disruption to patient treatment. During this interim period, the FDA will continue to restrict compounding of essentially copies of FDA-approved products. If the FDA encounters such compounding during an inspection or otherwise, the agency intends to take action, such as issuing a warning letter or pursuing an injunction,” the agency stated.


Previous publication Next publication

Media Center

  • 19 October 2018

    FDA Publishes Guidance on the Rare Disease Treatments

    FDA published draft guidance on October 15, 2018 to assist sponsors developing treatments for rare diseases plan for pre-investigational new drug application (pre-IND) meetings with FDA. In the guidance, the agency describes topics that should be considered in early drug development and pre-IND meetings.

  • 18 October 2018

    Russia emerges as frontrunner in global fight against tuberculosis

    Russia has turned out to be the world’s most successful tuberculosis fighter, Russian Health Minister Veronika Skvortsova stated  during the interview with the Rossiya-24 channel. "We are the global leader according to the pace in solving this issue," she noted, adding, "all countries acknowledge Russia’s foremost role here."

  • 17 October 2018

    Scientists developed new tool for open exchange of biomaterials

    A new easy-to-use legal tool that enables open exchange of biological materials was launched. The OpenMTA is a Material Transfer Agreement (MTA) designed to support openness, sharing and innovation in global biotechnology. Material Transfer Agreements (MTAs) provide the legal frameworks within which research organisations define terms and conditions for sharing their materials – everything from DNA molecules to plant seeds to patient samples.

  • 16 October 2018

    The First FDA-approved Digital Pill — What It Means for Pharma

    Last year, the U.S. Food and Drug Administration (FDA) approved what is perhaps the boldest use of digital technology in healthcare: a pill that is integrated with an ingestible sensor that captures information about whether the patient has complied with her medication regimen. A patient ingests the pill and it sends the data to a patch worn on her torso, which adds various physiologic measures. From there the information is wirelessly sent to a mobile phone app, allowing both the patient and her physician to track how the patient is using and responding to her medication.

Read more